Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
Alger Health Sciences C AHSCX
- NAV / 1-Day Return 13.08 / +0.08 %
- Total Assets 109.1 Mil
-
Adj. Expense Ratio
1.950%
- Expense Ratio 1.950%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 306%
USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:18 PM GMT+0
Morningstar’s Analysis AHSCX
Will AHSCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 47.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Amgen Inc | 5.49 | 6.2 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 5.29 | 6.0 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 5.21 | 5.9 Mil | Healthcare |
Stryker Corp | 5.19 | 5.8 Mil | Healthcare |
Eli Lilly and Co | 5.08 | 5.7 Mil | Healthcare |
Boston Scientific Corp | 5.04 | 5.7 Mil | Healthcare |
Intuitive Surgical Inc | 4.19 | 4.7 Mil | Healthcare |
UnitedHealth Group Inc | 4.13 | 4.6 Mil | Healthcare |
McKesson Corp | 4.06 | 4.6 Mil | Healthcare |
Novo Nordisk A/S ADR | 3.73 | 4.2 Mil | Healthcare |